Redox proteomics of oxidatively modified brain proteins in mild cognitive impairment

Neuroproteomics

Volumn , Issue , 2009, Pages 163-195

  Reed, Tanea T ^a   Sultana, Rukhsana ^b   Butterfield, D Allan ^b  

^a EASTERN KENTUCKY UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057690358     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (203)

1. Winblad, B., Palmer, K., Kivipelto, M. et al. (2004) Mild cognitive impairment-Beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment, J Intern Med 256:240-6.
2. Petersen, R. C. (2004) Mild cognitive impairment as a diagnostic entity, J Intern Med 256:183-94.
3. Almkvist, O., Basun, H., Backman, L. et al. (1998) Mild cognitive impairment-An early stage of Alzheimer’s disease? J Neural Transm Suppl 54:21-9.
4. Flicker, C., Ferris, S. H. and Reisberg, B. (1991) Mild cognitive impairment in the elderly: Predictors of dementia, Neurology 41:1006-9.
5. Luis, C. A., Loewenstein, D. A., Acevedo, A., Barker, W. W. and Duara, R. (2003) Mild cognitive impairment: Directions for future research, Neurology 61:438-44.
6. Morris, J. C., Storandt, M., Miller, J. P. et al. (2001) Mild cognitive impairment represents early-stage Alzheimer disease, Arch Neurol 58:397-405.
7. Portet, F., Ousset, P. J. and Touchon, J. (2005) What is a mild cognitive impairment? Rev Prat 55:1891-4.
8. Maioli, F., Coveri, M., Pagni, P. et al. (2007) Conversion of mild cognitive impairment to dementia in elderly subjects: A preliminary study in a memory and cognitive disorder unit, Arch Gerontol Geriatr 44 Suppl 1:233-41.
9. Rozzini, L., Chilovi, B. V., Conti, M. et al. (2007) Conversion of amnestic mild cognitive impairment to dementia of Alzheimer type is independent to memory deterioration, Int J Geriatr Psychiatry 22:1217-22.
10. Apostolova, L. G., Dutton, R. A., Dinov, I. D. et al. (2006) Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps, Arch Neurol 63:693-9.
11. Petersen, R. C. (2000) Mild cognitive impairment: Transition between aging and Alzheimer’s disease, Neurologia 15:93-101.
12. Petersen, R. C. (2003) Mild cognitive impairment clinical trials, Nat Rev Drug Discov 2:646-53.
13. de Leon, M. J., DeSanti, S., Zinkowski, R. et al. (2004) MRI and CSF studies in the early diagnosis of Alzheimer’s disease, J Intern Med 256:205-23.
14. Devanand, D. P., Pradhaban, G., Liu, X. et al. (2007) Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease, Neurology 68:828-36.
15. Jack, C. R., Jr., Petersen, R. C., Xu, Y. C. et al. (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment, Neurology 52:1397-1403.
16. Barnes, J., Godbolt, A. K., Frost, C. et al. (2007) Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD, Neurobiol Aging 28:20-8.
17. Du, A. T., Schuff, N., Amend, D. et al. (2001) Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer’s disease, J Neurol Neurosurg Psychiatry 71:441-7.
18. Du, A. T., Schuff, N., Kramer, J. H. et al. (2004) Higher atrophy rate of entorhinal cortex than hippocampus in AD, Neurology 62:422-7.
19. Mevel, K., Chetelat, G., Desgranges, B. and Eustache, F. (2006) Alzheimer’s disease, hippocampus and neuroimaging, Encephale 32 Pt 4:S1149-54.
20. Mori, E. (2005) Hippocampal atrophy and memory disturbance, No To Shinkei 57:1067-78.
21. Halliwell, B. (2006) Oxidative stress and neurodegeneration: Where are we now? J Neurochem 97:1634-58.
22. Brown, L. A., Harris, F. L. and Jones, D. P. (1997) Ascorbate deficiency and oxidative stress in the alveolar type II cell, Am J Physiol 273:L782-8.
23. Butterfield, D. A. and Kanski, J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins, Mech Aging Dev 122:945-62.
24. Butterfield, D. A. and Lauderback, C. M. (2002) Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress, Free Radic Biol Med 32:1050-60.
25. Giasson, B. I., Ischiropoulos, H., Lee, V. M. and Trojanowski, J. Q. (2002) The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer’s and Parkinson’s diseases, Free Radic Biol Med 32:1264-75.
26. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer’s disease, Free Radic Biol Med 23:134-47.
27. Zhu, X., Smith, M. A., Perry, G. and Aliev, G. (2004) Mitochondrial failures in Alzheimer’s disease, Am J Alzheimers Dis Other Demen 19:345-52.
28. Reed, T., Perluigi, M., Sultana, R. et al. (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment:Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer’s disease, Neurobiol Dis 30:107-20.
29. Keller, J. N., Schmitt, F. A., Scheff, S. W. et al. (2005) Evidence of increased oxidative damage in subjects with mild cognitive impairment, Neurology 64:1152-6.
30. Butterfield, D. A. and Stadtman, E. R. (1997) Protein oxidation processes in aging brain, Adv Cell Aging Gerontol 2:161-91.
31. Butterfield, D. A., Reed, T., Perluigi, M. et al. (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment, Neurosci Lett 397:170-3.
32. Butterfield, D. A., Reed, T. T., Perluigi, M. et al. (2007) Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: Implications for the role of nitration in the progression of Alzheimer’s disease, Brain Res 1148:243-8.
33. Dalle-Donne, I., Rossi, R., Colombo, R., Giustarini, D. and Milzani, A. (2006) Biomarkers of oxidative damage in human disease, Clin Chem 52:601-23.
34. Dalle-Donne, I., Scaloni, A., Giustarini, D. et al. (2005) Proteins as biomarkers of oxidative/nitrosative stress in diseases: the contribution of redox proteomics, Mass Spectrom Rev 24:55-99.
35. Levine, R. L., Garland, D., Oliver, C. N. et al. (1990) Determination of carbonyl content in oxidatively modified proteins, Methods Enzymol 186:464-78.
36. Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W. and Markesbery, W. R. (2001) Protein oxidation in the brain in Alzheimer’s disease, Neuroscience 103:373-83.
37. Stadtman, E. R. (2001) Protein oxidation in aging and age-related diseases, Ann NY Acad Sci 928:22-38.
38. Stadtman, E. R. and Berlett, B. S. (1997) Reactive oxygen-mediated protein oxidation in aging and disease, Chem Res Toxicol 10:485-94.
39. Loske, C., Neumann, A., Cunningham, A. M. et al. (1998) Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress, J Neural Transm 105:1005-15.
40. Munch, G., Schinzel, R., Loske, C. et al. (1998) Alzheimer’s disease-Synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts, J Neural Transm 105:439-61.
41. Esterbauer, H., Schaur, R. J. and Zollner, H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes, Free Radic Biol Med 11:81-128.
42. Pamplona, R., Dalfo, E., Ayala, V. et al. (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets, J Biol Chem 280:21522-30.
43. O’Brien, J. S. and Sampson, E. L. (1965) Lipid composition of the normal human brain:Gray matter, white matter, and myelin, J Lipid Res 6:537-44.
44. Skinner, E. R., Watt, C., Besson, J. A. and Best, P. V. (1993) Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer’s disease and control subjects, Brain 116 (Pt 3):717-25.
45. Montine, T. J., Neely, M. D., Quinn, J. F. et al. (2002) Lipid peroxidation in aging brain and Alzheimer’s disease, Free Radic Biol Med 33:620-6.
46. Perluigi, M., Sultana, R., Cenini, G., Di Domenico, F., Memo, M., Pierce, W. M., Coccia, R., and Butterfield, D. A. (2009) Redox Proteomics Identification of HNEModified Brain Proteins in Alzheimer’s Disease: Role of Lipid Peroxidaton in Alzheimer’s Disease Pathogenesis, Proteomics-Clin Appl 118:131-150.
47. Bader Lange, M. L., Cenini, G., Piroddi, M. et al. (2008) Loss of phospholipid asymmetry and elevated brain apoptotic protein levels in subjects with amnestic mild cognitive impairment and Alzheimer disease, Neurobiol Dis 29:456-64.
48. Williams, T. I., Lynn, B. C., Markesbery, W. R. and Lovell, M. A. (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer’s disease, Neurobiol Aging 27:1094-9.
49. Subramaniam, R., Roediger, F., Jordan, B. et al. (1997) The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins, J Neurochem 69:1161-9.
50. Tamagno, E., Robino, G., Obbili, A. et al. (2003) H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK, Exp Neurol 180:144-55.
51. Uchida, K. (2003) 4-Hydroxy-2-nonenal: A product and mediator of oxidative stress, Prog Lipid Res 42:318-43.
52. Camandola, S., Poli, G. and Mattson, M. P. (2000) The lipid peroxidation product 4-hydroxy-2,3-nonenal inhibits constitutive and inducible activity of nuclear factor kappa B in neurons, Brain Res Mol Brain Res 85:53-60.
53. Ding, Q., Markesbery, W. R., Chen, Q., Li, F. and Keller, J. N. (2005) Ribosome dysfunction is an early event in Alzheimer’s disease, J Neurosci 25:9171-5.
54. Drake, J., Petroze, R., Castegna, A. et al. (2004) 4-Hydroxynonenal oxidatively modifies histones: Implications for Alzheimer’s disease, Neurosci Lett 356:155-8.
55. Poot, M., Verkerk, A., Koster, J. F., Esterbauer, H. and Jongkind, J. F. (1988) Reversible inhibition of DNA and protein synthesis by cumene hydroperoxide and 4-hydroxy-nonenal, Mech Ageing Dev 43:1-9.
56. Uchida, K. and Stadtman, E. R. (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal, Proc Natl Acad Sci U S A 89:4544-8.
57. Okada, K., Wangpoengtrakul, C., Osawa, T. et al. (1999) 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules, J Biol Chem 274:23787-93.
58. Pratico, D., Clark, C. M., Liun, F. et al. (2002) Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease, Arch Neurol 59:972-6.
59. Alvarez, B. and Radi, R. (2003) Peroxynitrite reactivity with amino acids and proteins, Amino Acids 25:295-311.
60. Tien, M., Berlett, B. S., Levine, R. L., Chock, P. B. and Stadtman, E. R. (1999) Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration:pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation, Proc Natl Acad Sci U S A 96:7809-14.
61. Hazen, S. L., Gaut, J. P., Hsu, F. F. et al. (1997) p-Hydroxyphenylacetaldehyde, the major product of L-tyrosine oxidation by the myeloperoxidase-H2O2-chloride system of phagocytes, covalently modifies epsilon-amino groups of protein lysine residues, J Biol Chem 272:16990-8.
62. Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S. and Perry, G. (1997) Widespread peroxynitrite-mediated damage in Alzheimer’s disease, J Neurosci 17:2653-7.
63. Botti, H., Trostchansky, A., Batthyany, C. and Rubbo, H. (2005) Reactivity of peroxynitrite and nitric oxide with LDL, IUBMB Life 57:407-12.
64. Niles, J. C., Wishnok, J. S. and Tannenbaum, S. R. (2006) Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: Structures and mechanisms of product formation, Nitric Oxide 14:109-21.
65. Szabo, C. (1996) DNA strand breakage and activation of poly-ADP ribosyltransferase:A cytotoxic pathway triggered by peroxynitrite, Free Radic Biol Med 21:855-69.
66. Masuda, M., Nishino, H. and Ohshima, H. (2002) Formation of 8-nitroguanosine in cellular RNA as a biomarker of exposure to reactive nitrogen species, Chem Biol Interact 139:187-97.
67. Good, P. F., Werner, P., Hsu, A., Olanow, C. W. and Perl, D. P. (1996) Evidence of neuronal oxidative damage in Alzheimer’s disease, Am J Pathol 149:21-8.
68. Good, P. F., Hsu, A., Werner, P., Perl, D. P. and Olanow, C. W. (1998) Protein nitration in Parkinson’s disease, J Neuropathol Exp Neurol 57:338-42.
69. Drake, J., Kanski, J., Varadarajan, S., Tsoras, M. and Butterfield, D. A. (2002) Elevation of brain glutathione by gamma-glutamylcysteine ethyl ester protects against peroxynitrite- induced oxidative stress, J Neurosci Res 68:776-84.
70. Whiteman, M., Tritschler, H. and Halliwell, B. (1996) Protection against peroxynitritedependent tyrosine nitration and alpha 1-antiproteinase inactivation by oxidized and reduced lipoic acid, FEBS Lett 379:74-6.
71. Christen, S., Woodall, A. A., Shigenaga, M. K. et al. (1997) gamma-tocopherol traps mutagenic electrophiles such as NO(X) and complements alpha-tocopherol:Physiological implications, Proc Natl Acad Sci U S A 94:3217-22.
72. Anantharaman, M., Tangpong, J., Keller, J. N. et al. (2006) Beta-amyloid mediated nitration of manganese superoxide dismutase: Implication for oxidative stress in a APPNLH/NLH X PS-1P264L/P264L double knock-in mouse model of Alzheimer’s disease, Am J Pathol 168:1608-18.
73. Aoyama, K., Matsubara, K., Fujikawa, Y. et al. (2000) Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases, Ann Neurol 47:524-7.
74. Ischiropoulos, H., Zhu, L., Chen, J. et al. (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase, Arch Biochem Biophys 298:431-7.
75. MacMillan-Crow, L. A. and Thompson, J. A. (1999) Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite, Arch Biochem Biophys 366:82-8.
76. Hara, M. R., Cascio, M. B. and Sawa, A. (2006) GAPDH as a sensor of NO stress, Biochim Biophys Acta 1762:502-9.
77. Souza, J. M. and Radi, R. (1998) Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite, Arch Biochem Biophys 360:187-94.
78. Clements, M. K., Siemsen, D. W., Swain, S. D. et al. (2003) Inhibition of actin polymerization by peroxynitrite modulates neutrophil functional responses, J Leukoc Biol 73:344-55.
79. Neumann, P., Gertzberg, N., Vaughan, E. et al. (2006) Peroxynitrite mediates TNF-(alpha)-induced endothelial barrier dysfunction and nitration of actin, Am J Physiol Lung Cell Mol Physiol 290:L674-84.
80. Di Stasi, A. M., Mallozzi, C., Macchia, G. et al. (2002) Peroxynitrite affects exocytosis and SNARE complex formation and induces tyrosine nitration of synaptic proteins, J Neurochem 82:420-9.
81. Blanchard-Fillion, B., Souza, J. M., Friel, T. et al. (2001) Nitration and inactivation of tyrosine hydroxylase by peroxynitrite, J Biol Chem 276:46017-23.
82. Gow, A. J., Duran, D., Malcolm, S. and Ischiropoulos, H. (1996) Effects of peroxynitrite- induced protein modifications on tyrosine phosphorylation and degradation, FEBS Lett 385:63-6.
83. Butterfield, D. A., Poon, H. F., St Clair, D. et al. (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: Insights into the development of Alzheimer’s disease, Neurobiol Dis 22:223-32.
84. Wilkins, M. R., Sanchez, J. C., Gooley, A. A. et al. (1996) Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it, Biotechnol Genet Eng Rev 13:19-50.
85. Davidsson, P. and Sjogren, M. (2005) The use of proteomics in biomarker discovery in neurodegenerative diseases, Dis Markers 21:81-92.
86. Galasko, D. (2005) Biomarkers for Alzheimer’s disease-Clinical needs and application, J Alzheimers Dis 8:339-46.
87. Lee, J. W., Namkoong, H., Kim, H. K. et al. (2007) Fibrinogen gamma-A chain precursor in CSF: A candidate biomarker for Alzheimer’s disease, BMC Neurol 7:14.
88. Hortin, G. L., Jortani, S. A., Ritchie, J. C., Jr., Valdes, R., Jr. and Chan, D. W. (2006) Proteomics: A new diagnostic frontier, Clin Chem 52:1218-22.
89. Solassol, J., Boulle, N., Maudelonde, T. and Mange, A. (2005) Clinical proteomics:Towards early detection of cancers, Med Sci (Paris) 21:722-9.
90. Ho, L., Sharma, N., Blackman, L. et al. (2005) From proteomics to biomarker discovery in Alzheimer’s disease, Brain Res Rev 48:360-9.
91. Simonsen, A. H., McGuire, J., Hansson, O. et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment, Arch Neurol 64:366-70.
92. Zhang, J., Goodlett, D. R., Quinn, J. F. et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease, J Alzheimers Dis 7:125-33; discussion 173-80.
93. Poon, H. F., Vaishnav, R. A., Getchell, T. V., Getchell, M. L. and Butterfield, D. A. (2006) Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice, Neurobiol Aging 27:1010-9.
94. Boguski, M. S. and McIntosh, M. W. (2003) Biomedical informatics for proteomics, Nature 422:233-7.
95. Maurer, H. H. and Peters, F. T. (2005) Toward high-throughput drug screening using mass spectrometry, Ther Drug Monit 27:686-8.
96. Thongboonkerd, V., McLeish, K. R., Arthur, J. M. and Klein, J. B. (2002) Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation, Kidney Int 62:1461-9.
97. Aebersold, R. and Goodlett, D. R. (2001) Mass spectrometry in proteomics, Chem Rev 101:269-95.
98. Domon, B. and Aebersold, R. (2006) Mass spectrometry and protein analysis, Science 312:212-7.
99. Gygi, S. P. and Aebersold, R. (2000) Mass spectrometry and proteomics, Curr Opin Chem Biol 4:489-94.
100. Aksenov, M., Aksenova, M., Butterfield, D. A. and Markesbery, W. R. (2000) Oxidative modification of creatine kinase BB in Alzheimer’s disease brain, J Neurochem 74:2520-7.
101. Poon, H. F., Frasier, M., Shreve, N. et al. (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-A model of familial Parkinson’s disease, Neurobiol Dis 18:492-8.
102. Butterfield, D. A. and Castegna, A. (2003) Proteomic analysis of oxidatively modified proteins in Alzheimer’s disease brain: Insights into neurodegeneration, Cell Mol Biol (Noisy-le-grand) 49:747-51.
103. Hensley, K., Hall, N., Subramaniam, R. et al. (1995) Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation, J Neurochem 65:2146-56.
104. Sultana, R., Boyd-Kimball, D., Poon, H. F. et al. (2006) Oxidative modification and down-regulation of Pin1 in Alzheimer’s disease hippocampus: A redox proteomics analysis, Neurobiol Aging 27:918-25.
105. Tangpong, J., Cole, M. P., Sultana, R. et al. (2007) Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain, J Neurochem 100:191-201.
106. Scheff, S. W., Price, D. A., Schmitt, F. A. and Mufson, E. J. (2006) Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment, Neurobiol Aging 27:1372-84.
107. Cao, Q., Jiang, K., Zhang, M. et al. (2003) Brain glucose metabolism and neuropsychological test in patients with mild cognitive impairment, Chin Med J (Engl) 116:1235-8.
108. Geddes, J. W., Pang, Z. and Wiley, D. H. (1996) Hippocampal damage and cytoskeletal disruption resulting from impaired energy metabolism. Implications for Alzheimer disease, Mol Chem Neuropathol 28:65-74.
109. Messier, C. and Gagnon, M. (1996) Glucose regulation and cognitive functions: Relation to Alzheimer’s disease and diabetes, Behav Brain Res 75:1-11.
110. Vanhanen, M. and Soininen, H. (1998) Glucose intolerance, cognitive impairment and Alzheimer’s disease, Curr Opin Neurol 11:673-7.
111. Boyd-Kimball, D., Castegna, A., Sultana, R. et al. (2005) Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: Implications for Alzheimer’s disease, Brain Res 1044:206-15.
112. Castegna, A., Aksenov, M., Thongboonkerd, V. et al. (2002) Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: Dihydropyrimidinaserelated protein 2, alpha-enolase and heat shock cognate 71, J Neurochem 82:1524-32.
113. Castegna, A., Thongboonkerd, V., Klein, J. B. et al. (2003) Proteomic identification of nitrated proteins in Alzheimer’s disease brain, J Neurochem 85:1394-401.
114. Poon, H. F., Castegna, A., Farr, S. A. et al. (2004) Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-acceleratedprone 8 mice brain, Neuroscience 126:915-26.
115. Sultana, R., Boyd-Kimball, D., Poon, H. F. et al. (2006) Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD, Neurobiol Aging 27:1564-76.
116. Sultana, R., Perluigi, M. and Butterfield, D. A. (2006) Redox proteomics identification of oxidatively modified proteins in Alzheimer’s disease brain and in vivo and in vitro models of AD centered around Abeta(1-42), J Chromatogr B Analyt Technol Biomed Life Sci 833:3-11.
117. Kida, K., Nishio, T., Nagai, K., Matsuda, H. and Nakagawa, H. (1982) Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity, J Biochem (Tokyo) 91:755-60.
118. Hoyer, S. (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease, Eur J Pharmacol 490:115-25.
119. Rapoport, S. I. (1999) Functional brain imaging in the resting state and during activation in Alzheimer’s disease. Implications for disease mechanisms involving oxidative phosphorylation, Ann N Y Acad Sci 893:138-53.
120. Duan, Z., Lamendola, D. E., Yusuf, R. Z. et al. (2002) Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype, Anticancer Res 22:1933-41.
121. Keller, J. N., Mark, R. J., Bruce, A. J. et al. (1997) 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes, Neuroscience 80:685-96.
122. Mattson, M. P. (2004) Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders, Ann N Y Acad Sci 1012:37-50.
123. Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A. et al. (1996) Glutamine synthetase- induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation, J Neurochem 66:2050-6.
124. Butterfield, D. A., Hensley, K., Cole, P. et al. (1997) Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics:Relevance to Alzheimer’s disease, J Neurochem 68:2451-7.
125. Howard, B. J., Yatin, S., Hensley, K. et al. (1996) Prevention of hyperoxia-induced alterations in synaptosomal membrane-associated proteins by N-tert-butyl-alphaphenylnitrone and 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (Tempol), J Neurochem 67:2045-50.
126. Lamprecht, R. and LeDoux, J. (2004) Structural plasticity and memory, Nat Rev Neurosci 5:45-54.
127. Ikonomovic, M. D., Mufson, E. J., Wuu, J. et al. (2003) Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer’s neuropathology, J Alzheimers Dis 5:39-48.
128. Lee, H. G., Zhu, X., Ghanbari, H. A. et al. (2002) Differential regulation of glutamate receptors in Alzheimer’s disease, Neurosignals 11:282-92.
129. Sergeant, N., Wattez, A., Galvan-valencia, M. et al. (2003) Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer’s disease, Neuroscience 117:293-303.
130. Butterfield, D. A., Castegna, A., Lauderback, C. M. and Drake, J. (2002) Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death, Neurobiol Aging 23:655-64.
131. Butterfield, D. A., Drake, J., Pocernich, C. and Castegna, A. (2001) Evidence of oxidative damage in Alzheimer’s disease brain: Central role for amyloid beta-peptide, Trends Mol Med 7:548-54.
132. Hinault, M. P., Ben-Zvi, A. and Goloubinoff, P. (2006) Chaperones and proteases:Cellular fold-controlling factors of proteins in neurodegenerative diseases and aging, J Mol Neurosci 30:249-65.
133. Sultana, R., Reed, T., Perluigi, M. et al. (2007) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: A regional study, J Cell Mol Med 11:839-51.
134. Perluigi, M., Fai Poon, H., Hensley, K. et al. (2005) Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-A model of familial amyotrophic lateral sclerosis, Free Radic Biol Med 38:960-8.
135. Magrane, J., Smith, R. C., Walsh, K. and Querfurth, H. W. (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons, J Neurosci 24:1700-6.
136. Schutkowski, M., Bernhardt, A., Zhou, X. Z. et al. (1998) Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition, Biochemistry 37:5566-75.
137. Holzer, M., Gartner, U., Stobe, A. et al. (2002) Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus, Acta Neuropathol 104:471-81.
138. Kurt, M. A., Davies, D. C., Kidd, M., Duff, K. and Howlett, D. R. (2003) Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes, Neurobiol Dis 14:89-97.
139. Ramakrishnan, P., Dickson, D. W. and Davies, P. (2003) Pin1 colocalization with phosphorylated tau in Alzheimer’s disease and other tauopathies, Neurobiol Dis 14:251-64.
140. Sultana, R., Boyd-Kimball, D., Poon, H. F. et al. (2005) Redox proteomics identification of oxidized proteins in Alzheimer’s disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD, Neurobiol Aging 27:1564-76.
141. Lu, P. J., Wulf, G., Zhou, X. Z., Davies, P. and Lu, K. P. (1999) The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein, Nature 399:784-8.
142. Butterfield, D. A., Abdul, H. M., Opii, W. et al. (2006) Pin1 in Alzheimer’s disease, J Neurochem 98:1697-706.
143. Lauderback, C. M., Hackett, J. M., Huang, F. F. et al. (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: The role of Abeta1-42, J Neurochem 78:413-6.
144. Sultana, R. and Butterfield, D. A. (2004) Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: Implications for accumulation of reactive lipid peroxidation products, Neurochem Res 29:2215-20.
145. Xie, C., Lovell, M. A., Xiong, S. et al. (2001) Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress, Free Radic Biol Med 31:73-81.
146. Peshenko, I. V. and Shichi, H. (2001) Oxidation of active center cysteine of bovine 1-Cys peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxynitrite, Free Radic Biol Med 31:292-303.
147. Akman, S. A., O’Connor, T. R. and Rodriguez, H. (2000) Mapping oxidative DNA damage and mechanisms of repair, Ann N Y Acad Sci 899:88-102.
148. Doorn, J. A., Maser, E., Blum, A., Claffey, D. J. and Petersen, D. R. (2004) Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal, Biochemistry 43:13106-14.
149. Balcz, B., Kirchner, L., Cairns, N., Fountoulakis, M. and Lubec, G. (2001) Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer’s disease, J Neural Transm Suppl 6:193-201.
150. Lemieux, N., Malfoy, B. and Forrest, G. L. (1993) Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells, Genomics 15:169-72.
151. Korenberg, J. R., Bradley, C. and Disteche, C. M. (1992) Down syndrome: Molecular mapping of the congenital heart disease and duodenal stenosis, Am J Hum Genet 50:294-302.
152. Kim, S. H., Fountoulakis, M., Cairns, N. and Lubec, G. (2001) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer’s disease and Down syndrome, J Neural Transm Suppl 6:223-35.
153. Krapfenbauer, K., Engidawork, E., Cairns, N., Fountoulakis, M. and Lubec, G. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders, Brain Res 967:152-60.
154. Schonberger, S. J., Edgar, P. F., Kydd, R., Faull, R. L. and Cooper, G. J. (2001) Proteomic analysis of the brain in Alzheimer’s disease: molecular phenotype of a complex disease process, Proteomics 1:1519-28.
155. Sultana, R., Boyd-Kimball, D., Cai, J. et al. (2007) Proteomics analysis of the Alzheimer’s disease hippocampal proteome, J Alzheimers Dis 11:153-64.
156. Mecocci, P. (2004) Oxidative stress in mild cognitive impairment and Alzheimer disease:A continuum, J Alzheimers Dis 6:159-63.
157. Hamajima, N., Matsuda, K., Sakata, S. et al. (1996) A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution, Gene 180:157-63.
158. Kato, Y., Hamajima, N., Inagaki, H. et al. (1998) Post-meiotic expression of the mouse dihydropyrimidinase-related protein 3 (DRP-3) gene during spermiogenesis, Mol Reprod Dev 51:105-11.
159. Lubec, G., Nonaka, M., Krapfenbauer, K. et al. (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level, J Neural Transm Suppl 57:161-77.
160. Yoshida, H., Watanabe, A. and Ihara, Y. (1998) Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer’s disease, J Biol Chem 273:9761-8.
161. Weitzdoerfer, R., Fountoulakis, M. and Lubec, G. (2001) Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain, J Neural Transm Suppl:95-107.
162. Coleman, P. D. and Flood, D. G. (1987) Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease, Neurobiol Aging 8:521-45.
163. Arnaiz, E. and Almkvist, O. (2003) Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease, Acta Neurol Scand Suppl 179:34-41.
164. Rami, L., Molinuevo, J. L., Sanchez-Valle, R., Bosch, B. and Villar, A. (2007) Screening for amnestic mild cognitive impairment and early Alzheimer’s disease with M@T (Memory Alteration Test) in the primary care population, Int J Geriatr Psychiatry 22:294-304.
165. Yamashiro, S., Yamakita, Y., Ono, S. and Matsumura, F. (1998) Fascin, an actin-bundling protein, induces membrane protrusions and increases cell motility of epithelial cells, Mol Biol Cell 9:993-1006.
166. Adams, J. C. (1995) Formation of stable microspikes containing actin and the 55 kDa actin bundling protein, fascin, is a consequence of cell adhesion to thrombospondin-1:Implications for the anti-adhesive activities of thrombospondin-1, J Cell Sci 108 (Pt 5):1977-90.
167. Adams, J. C. (2004) Roles of fascin in cell adhesion and motility, Curr Opin Cell Biol 16:590-6.
168. Pinkus, G. S., Lones, M. A., Matsumura, F. et al. (2002) Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker, Am J Clin Pathol 118:335-43.
169. Graziewicz, M. A., Day, B. J. and Copeland, W. C. (2002) The mitochondrial DNA polymerase as a target of oxidative damage, Nucleic Acids Res 30:2817-24.
170. Anilkumar, N., Parsons, M., Monk, R., Ng, T. and Adams, J. C. (2003) Interaction of fascin and protein kinase Calpha: a novel intersection in cell adhesion and motility, Embo J 22:5390-402.
171. Opii, W. O., Joshi, G., Head, E. et al. (2008) Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: Relevance to Alzheimer’s disease, Neurobiol Aging 29:51-70.
172. Battaini, F., Pascale, A., Lucchi, L., Pasinetti, G. M. and Govoni, S. (1999) Protein kinase C anchoring deficit in postmortem brains of Alzheimer’s disease patients, Exp Neurol 159:559-64.
173. Goldman, J. E. (1983) Immunocytochemical studies of actin localization in the central nervous system, J Neurosci 3:1952-62.
174. Masliah, E., Mallory, M., Hansen, L. et al. (1994) Synaptic and neuritic alterations during the progression of Alzheimer’s disease, Neurosci Lett 174:67-72.
175. Dougherty, M. K. and Morrison, D. K. (2004) Unlocking the code of 14-3-3, J Cell Sci 117:1875-84.
176. Takahashi, Y. (2003) The 14-3-3 proteins: Gene, gene expression, and function, Neurochem Res 28:1265-73.
177. Sugimori, K., Kobayashi, K., Kitamura, T., Sudo, S. and Koshino, Y. (2007) 14-3-3 protein beta isoform is associated with 3-repeat tau neurofibrillary tangles in Alzheimer’s disease, Psychiatry Clin Neurosci 61:159-67.
178. Frautschy, S. A., Baird, A. and Cole, G. M. (1991) Effects of injected Alzheimer betaamyloid cores in rat brain, Proc Natl Acad Sci U S A 88:8362-6.
179. Layfield, R., Fergusson, J., Aitken, A. et al. (1996) Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins, Neurosci Lett 209:57-60.
180. Burkhard, P. R., Sanchez, J. C., Landis, T. and Hochstrasser, D. F. (2001) CSF detection of the 14-3-3 protein in unselected patients with dementia, Neurology 56:1528-33.
181. Poon, H. F., Shepherd, H. M., Reed, T. T. et al. (2006) Proteomics analysis provides insight into caloric restriction mediated oxidation and expression of brain proteins associated with age-related impaired cellular processes: Mitochondrial dysfunction, glutamate dysregulation and impaired protein synthesis, Neurobiol Aging 27:1020-34.
182. Boyd-Kimball, D., Sultana, R., Poon, H. F. et al. (2005) Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: Implications for Alzheimer’s disease, Neuroscience 132:313-24.
183. Agarwal-Mawal, A., Qureshi, H. Y., Cafferty, P. W. et al. (2003) 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex, J Biol Chem 278:12722-8.
184. Hashiguchi, M., Sobue, K. and Paudel, H. K. (2000) 14-3-3 zeta is an effector of tau protein phosphorylation, J Biol Chem 275:25247-54.
185. Hernandez, F., Cuadros, R. and Avila, J. (2004) Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers, Neurosci Lett 357:143-6.
186. Ojika, K., Tsugu, Y., Mitake, S., Otsuka, Y. and Katada, E. (1998) NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro, Brain Res Dev Brain Res 106:173-80.
187. Jouvenceau, A., Dutar, P. and Billard, J. M. (1998) Alteration of NMDA receptormediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits, Hippocampus 8:627-37.
188. Davies, P. and Terry, R. D. (1981) Cortical somatostatin-like immunoreactivity in cases of Alzheimer’s disease and senile dementia of the Alzheimer type, Neurobiol Aging 2:9-14.
189. Davis, B. M., Mohs, R. C., Greenwald, B. S. et al. (1985) Clinical studies of the cholinergic deficit in Alzheimer’s disease. I. Neurochemical and neuroendocrine studies, J Am Geriatr Soc 33:741-8.
190. Perry, E. K., Perry, R. H., Smith, C. J. et al. (1986) Cholinergic receptors in cognitive disorders, Can J Neurol Sci 13:521-7.
191. Rossor, M. N., Iversen, L. L., Johnson, A. J., Mountjoy, C. Q. and Roth, M. (1981) Cholinergic deficit in frontal cerebral cortex in Alzheimer’s disease is age dependent, Lancet 2:1422.
192. Ling, M., Merante, F., Chen, H. S. et al. (1997) The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene, Gene 197:325-36.
193. Orrenius, S., Burgess, D. H., Hampton, M. B. and Zhivotovsky, B. (1997) Mitochondria as the focus of apoptosis research, Cell Death Differ 4:427-8.
194. Vayssiere, J. L., Cordeau-Lossouarn, L., Larcher, J. C. et al. (1992) Participation of the mitochondrial genome in the differentiation of neuroblastoma cells, In Vitro Cell Dev Biol 28A:763-72.
195. Pestova, T. V. and Hellen, C. U. (2000) The structure and function of initiation factors in eukaryotic protein synthesis, Cell Mol Life Sci 57:651-74.
196. Thompson, J. E., Hopkins, M. T., Taylor, C. and Wang, T. W. (2004) Regulation of senescence by eukaryotic translation initiation factor 5A: Implications for plant growth and development, Trends Plant Sci 9:174-9.
197. Tome, M. E., Fiser, S. M., Payne, C. M. and Gerner, E. W. (1997) Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis, Biochem J 328 (Pt 3):847-54.
198. Chang, R. C., Wong, A. K., Ng, H. K. and Hugon, J. (2002) Phosphorylation of eukaryotic initiation factor-2 alpha (eIF2α) is associated with neuronal degeneration in Alzheimer’s disease, Neuroreport 13:2429-32.
199. Ferrer, I. (2002) Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer’s disease and Creutzfeldt-Jakob’s disease, Neuropathol Appl Neurobiol 28:441-51.
200. Li, X., An, W. L., Alafuzoff, I. et al. (2004) Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain, Neuroreport 15:2237-40.
201. Sajdel-Sulkowska, E. M. and Marotta, C. A. (1984) Alzheimer’s disease brain: Alterations in RNA levels and in a ribonuclease-inhibitor complex, Science 225:947-9.
202. Ding, Q., Markesbery, W. R., Cecarini, V. and Keller, J. N. (2006) Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer’s disease, Neurochem Res 31:705-10.
203. Sultana, R., Poon, H. F., Cai, J. et al. (2006) Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach, Neurobiol Dis 22:76-87.